Get the Stockscreener App
3.97
3.17%
-0.13
After Hours:
3.99
0.02
+0.50%
Orchestra Biomed Holdings Inc stock is traded at $3.97, with a volume of 157.04K.
It is down -3.17% in the last 24 hours and up +6.72% over the past month.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
See More
Previous Close:
$4.10
Open:
$4.12
24h Volume:
157.04K
Relative Volume:
0.72
Market Cap:
$237.73M
Revenue:
$32.72M
Net Income/Loss:
$-54.64M
P/E Ratio:
-3.5204
EPS:
-1.1277
Net Cash Flow:
$-55.08M
1W Performance:
+0.51%
1M Performance:
+6.72%
6M Performance:
-7.67%
1Y Performance:
+28.48%
1-Day Range:
$3.915
$4.14
1-Week Range:
$3.915
$4.17
52-Week Range:
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
3.97 | 245.51M | 32.72M | -54.64M | -55.08M | -1.1277 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
OBIO Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesRevenue Recognition Risk - newsline.com
Orchestra BioMed (OBIO) Edges Higher, Testing Key Resistance Zone on Modest VolumeLow Beta Factor - newsline.com
Orchestra BioMed (NASDAQ: OBIO) CFO has shares withheld to cover RSU tax obligations - Stock Titan
Orchestra BioMed (OBIO) insider uses 6,566 shares to cover RSU taxes - Stock Titan
Orchestra BioMed Grants Equity Awards to New Employees - MyChesCo
Number of shareholders of Orchestra BioMed Holdings, Inc. – NASDAQ:OBIO - TradingView
Orchestra BioMed Holdings (OBIO) Slips 2.26% as Shares Test Support Near $3.70Chart Pattern Alerts - newsline.com
Orchestra BioMed receives $20 million from Medtronic - Investing.com
OBIO: Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value - TradingView
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Insider Sell Alert: Darren Sherman Sells Shares of Orchestra Bio - GuruFocus
Insider Sell Alert: Darren Sherman Sells Shares of Orchestra BioMed Holdings Inc (OBIO) - GuruFocus
Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy - Stock Titan
Orchestra BioMed (OBIO) director Darren Sherman sells 15,000 shares under 10b5-1 plan - Stock Titan
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Affiliate sale notice: OBIO (NASDAQ: OBIO) proposes sale of 15,000 shares - Stock Titan
OBIO Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances PipelineAnnual Report - newsline.com
Orchestra BioMed Holdings (OBIO) Slides 1.76% as Shares Test Key Support LevelsIron Condor Alert - thelegaladvocate.com
OBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pre-Revenue StageHigh Growth Earnings - newsline.com
Orchestra BioMed (OBIO) CFO has 3,076 RSU shares withheld for taxes - Stock Titan
Orchestra BioMed (OBIO) insider reports RSU tax-withholding of 4,925 shares - Stock Titan
OBIO Q1 2026 Earnings: Loss Narrows More Than Expected, Stock Modestly DeclinesAnnual Earnings Summary - newsline.com
Orchestra BioMed (OBIO) Edges Higher: Navigating Key Support and Resistance LevelsPullback Trade - The Legal Advocate
OBIO Q1 2026 Earnings: EPS Beat Narrowed Losses, But No Revenue YetStrong Earnings Momentum - The Legal Advocate
OBIO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline in Pre-Revenue Phase - Newser
Orchestra BioMed Holdings (OBIO) Slips Slightly as Stock Hovers Near SupportBreakaway Gap - newsline.com
OBIO Q1 2026 Earnings: Narrowed Loss as EPS Surpasses Estimates; Stock Posts Modest DeclineLong-Term Guidance - Newser
Orchestra BioMed Advances FDA Path for Hypertension Device - MyChesCo
Orchestra BioMed Targets 2027 Data for Hypertension Trial - MyChesCo
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
Orchestra BioMed director Jason buys $2,493 in stock - Investing.com UK
Orchestra BioMed director Jason buys $2,493 in stock By Investing.com - Investing.com Canada
Orchestra BioMed (OBIO) director adds 665 shares in open-market buy - Stock Titan
Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68 - MSN
Orchestra BioMed CEO David Hochman buys $18,850 in company stock By Investing.com - Investing.com Nigeria
Orchestra BioMed director Aryeh Jason buys $34,986 in stock By Investing.com - Investing.com Nigeria
Orchestra BioMed director Aryeh Jason buys $34,986 in stock - Investing.com India
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Orchestra BioMed CEO David Hochman buys $18,850 in company stock - Investing.com
Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market - Stock Titan
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating - marketscreener.com
Orchestra BioMed director Fain buys $82,600 in shares By Investing.com - Investing.com South Africa
Orchestra BioMed director Fain buys $82,600 in shares - Investing.com UK
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):